A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase of Trial: Phase III
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Zanubrutinib (Primary) ; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms ALPINE
- Sponsors BeiGene
- 12 Nov 2019 According to a BeiGene media release, the company expects to complete the enrollment in 2019 or early 2020.
- 06 Nov 2019 Trial design released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology